Fig. 1From: Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trialPatient Consort. Patients received 10 doses up till week 56 and were subsequently followed until week 104. Week 104 defined the end of studyBack to article page